Pepijn Vemer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pepijn Vemer has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Maureen P. M. H. Rutten-Van MölKen
Erasmus School of Health Policy & Management, Erasmus Universiteit Rotterdam, Rotterdam, The Netherlands
7 shared publications - Mark Oppe
Section Medical Psychology and Psychotherapy, Department of Psychiatry, Erasmus MC, Erasmus University, Rotterdam, The Netherlands
3 shared publications - Talitha L. Feenstra
University of Groningen, Faculty of Science and Engineering, Groningen Research Institute of Pharmacy, Groningen, the Netherlands
3 shared publications - Isaac Corro Ramos
Institute for Medical Technology Assessment, Erasmus University, Rotterdam, the Netherlands
2 shared publications M.J. Al
2 shared publications- Maiwenn Al
Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 20 September 2017
- Published by Springer Nature in PharmacoEconomics
- Vol. 36 (1) , 105-113
Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research
The costs of performing research are an important input in value of information (VOI) analyses but are difficult to assess.
- 20 September 2017
- Published by Springer Nature in PharmacoEconomics
- Vol. 36 (1) , 105-113
Open AccessResearch Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research
The costs of performing research are an important input in value of information (VOI) analyses but are difficult to assess.
- Open Access
- 2 February 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (2) , e0171292
Mix and match. A simulation study on the impact of mixed-treatment comparison methods on health-economic outcomes
Decision-analytic cost-effectiveness (CE) models combine many parameters, often obtained after meta-analysis. We compared different methods of mixed-treatment comparison (MTC) to combine transition and event probabilities derived from several trials, especially with respect to health-economic (HE) outcomes like (quality adjusted) life years and costs. Trials were drawn from a simulated reference population, comparing two of four fictitious interventions. The goal was to estimate the CE between two of these. The amount of heterogeneity between trials was varied in scenarios. Parameter estimates were combined using direct comparison, MTC methods proposed by Song and Puhan, and Bayesian generalized linear fixed effects (GLMFE) and random effects models (GLMRE). Parameters were entered into a Markov model. Parameters and HE outcomes were compared with the reference population using coverage, statistical power, bias and mean absolute deviation (MAD) as performance indicators. Each analytical step was repeated 1,000 times. The direct comparison was outperformed by the MTC methods on all indicators, Song’s method yielded low bias and MAD, but uncertainty was overestimated. Puhan’s method had low bias and MAD and did not overestimate uncertainty. GLMFE generally had the lowest bias and MAD, regardless of the amount of heterogeneity, but uncertainty was overestimated. GLMRE showed large bias and MAD and overestimated uncertainty. Song’s and Puhan’s methods lead to the least amount of uncertainty, reflected in the shape of the CE acceptability curve. GLMFE showed slightly more uncertainty. Combining direct and indirect evidence is superior to using only direct evidence. Puhan’s method and GLMFE are preferred.
- 2 February 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (2) , e0171292
Open AccessMix and match. A simulation study on the impact of mixed-treatment comparison methods on health-economic outcomes
Decision-analytic cost-effectiveness (CE) models combine many parameters, often obtained after meta-analysis. We compared different methods of mixed-treatment comparison (MTC) to combine transition and event probabilities derived from several trials, especially with respect to health-economic (HE) outcomes like (quality adjusted) life years and costs. Trials were drawn from a simulated reference population, comparing two of four fictitious interventions. The goal was to estimate the CE between two of these. The amount of heterogeneity between trials was varied in scenarios. Parameter estimates were combined using direct comparison, MTC methods proposed by Song and Puhan, and Bayesian generalized linear fixed effects (GLMFE) and random effects models (GLMRE). Parameters were entered into a Markov model. Parameters and HE outcomes were compared with the reference population using coverage, statistical power, bias and mean absolute deviation (MAD) as performance indicators. Each analytical step was repeated 1,000 times. The direct comparison was outperformed by the MTC methods on all indicators, Song’s method yielded low bias and MAD, but uncertainty was overestimated. Puhan’s method had low bias and MAD and did not overestimate uncertainty. GLMFE generally had the lowest bias and MAD, regardless of the amount of heterogeneity, but uncertainty was overestimated. GLMRE showed large bias and MAD and overestimated uncertainty. Song’s and Puhan’s methods lead to the least amount of uncertainty, reflected in the shape of the CE acceptability curve. GLMFE showed slightly more uncertainty. Combining direct and indirect evidence is superior to using only direct evidence. Puhan’s method and GLMFE are preferred.
- Open Access
- 1 November 2016
- Published by Elsevier in Leukemia Research
- Vol. 50, 37-45
Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands
- 1 November 2016
- Published by Elsevier in Leukemia Research
- Vol. 50, 37-45
Open AccessCost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands
- Open Access
- 1 October 2013
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. 9, 1637-1645
Let’s get back to work: survival analysis on the return-to-work after depression
Purpose: Absence from work due to mental disorders is substantial. Additionally, long-term absence from work is associated with a reduced probability of return-to-work (RTW). Major depressive disorder (MDD) is a prevalent condition in Dutch occupational health care settings. An early estimate of the prognosis regarding RTW in patients with MDD could serve both as a point of departure for the identification of high-risk cases and as an instrument to monitor the course of the disorder and of RTW. In the current study, we aimed to assess the added value of health-related quality of life (HRQoL) and severity of depression to predict the time to RTW. Patients and methods: Data were derived from a prospective longitudinal study aimed to evaluate the cost effectiveness of a collaborative care treatment in sick-listed workers with MDD. We included demographic, job-related, and health-related variables. Severity of depression was measured using the Patient Health Questionnaire Depression Scale-9 (PHQ-9). HRQoL was measured using two generic preference-based instruments, the EuroQol 5-Dimension (EQ-5D™) and the Medical Outcomes Study Short Form Health Survey (SF-36). A survival model was constructed by applying different survival functions to assess the best fit for the data. Additionally, survival analyses were performed to assess the added value of the two HRQoL measures and depression severity for predicting RTW. Results: Females and older patients had a longer time to RTW. The same was true for patients with a full-time job and patients with more decision latitude. Patients in a management position and patients with more social support had a shorter time to RTW. Severity of depression was not predictive for the time to RTW. HRQoL measured by the SF-36 was a significant predictor for the time to RTW. Conclusion: HRQoL emerged as a significant predictor for the time to RTW. However, severity of depression was not predictive for the time to RTW. These results suggest the importance of assessing HRQoL in addition to severity of disease to assess functionality.
- 1 October 2013
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. 9, 1637-1645
Open AccessLet’s get back to work: survival analysis on the return-to-work after depression
Purpose: Absence from work due to mental disorders is substantial. Additionally, long-term absence from work is associated with a reduced probability of return-to-work (RTW). Major depressive disorder (MDD) is a prevalent condition in Dutch occupational health care settings. An early estimate of the prognosis regarding RTW in patients with MDD could serve both as a point of departure for the identification of high-risk cases and as an instrument to monitor the course of the disorder and of RTW. In the current study, we aimed to assess the added value of health-related quality of life (HRQoL) and severity of depression to predict the time to RTW. Patients and methods: Data were derived from a prospective longitudinal study aimed to evaluate the cost effectiveness of a collaborative care treatment in sick-listed workers with MDD. We included demographic, job-related, and health-related variables. Severity of depression was measured using the Patient Health Questionnaire Depression Scale-9 (PHQ-9). HRQoL was measured using two generic preference-based instruments, the EuroQol 5-Dimension (EQ-5D™) and the Medical Outcomes Study Short Form Health Survey (SF-36). A survival model was constructed by applying different survival functions to assess the best fit for the data. Additionally, survival analyses were performed to assess the added value of the two HRQoL measures and depression severity for predicting RTW. Results: Females and older patients had a longer time to RTW. The same was true for patients with a full-time job and patients with more decision latitude. Patients in a management position and patients with more social support had a shorter time to RTW. Severity of depression was not predictive for the time to RTW. HRQoL measured by the SF-36 was a significant predictor for the time to RTW. Conclusion: HRQoL emerged as a significant predictor for the time to RTW. However, severity of depression was not predictive for the time to RTW. These results suggest the importance of assessing HRQoL in addition to severity of disease to assess functionality.
- 1 September 2013
- Published by Elsevier in Value in Health
- Vol. 16 (6) , 1106-1107
Improving Model Validation in Health Technology Assessment: Comments on Guidelines of the ISPOR-SMDM Modeling Good Research Practices Task Force
- 1 September 2013
- Published by Elsevier in Value in Health
- Vol. 16 (6) , 1106-1107
Improving Model Validation in Health Technology Assessment: Comments on Guidelines of the ISPOR-SMDM Modeling Good Research Practices Task Force
- 27 August 2013
- Published by Springer Nature in PharmacoEconomics
- Vol. 31 (10) , 863-876
The Road Not Taken: Transferability Issues in Multinational Trials
National regulatory agencies often have to use cost-effectiveness (CE) data from multinational randomized controlled trials (RCTs) for national decision making on reimbursement of new drugs. We need to make the best use of these patient-level data to obtain estimates of country-specific CE. Several methods, ranging from simple to statistically complex, have existed for years. We investigated which of these methods are used to estimate CE ratios in economic evaluations performed alongside recent, multinational RCTs that enrolled at least 500 patients.
- 27 August 2013
- Published by Springer Nature in PharmacoEconomics
- Vol. 31 (10) , 863-876
The Road Not Taken: Transferability Issues in Multinational Trials
National regulatory agencies often have to use cost-effectiveness (CE) data from multinational randomized controlled trials (RCTs) for national decision making on reimbursement of new drugs. We need to make the best use of these patient-level data to obtain estimates of country-specific CE. Several methods, ranging from simple to statistically complex, have existed for years. We investigated which of these methods are used to estimate CE ratios in economic evaluations performed alongside recent, multinational RCTs that enrolled at least 500 patients.
- 5 June 2013
- Published by Springer Nature in PharmacoEconomics
- Vol. 31 (8) , 719-730
A Choice That Matters?
Background Decision-analytic cost-effectiveness (CE) models combine many different parameters like transition probabilities, event probabilities, utilities and costs, which are often obtained after meta-analysis. The method of meta-analysis may affect the CE estimate. Aim Our aim was to perform a simulation study that compares the performance of different methods of meta-analysis, especially with respect to model-based health economic (HE) outcomes. Methods A reference patient population of 50,000 was simulated from which sets of samples were drawn. Each sample drawn represented a clinical trial comparing two fictitious interventions. In several scenarios, the heterogeneity between these trials was varied, by drawing one or more of the trials from predefined subpopulations. Parameter estimates from these trials were combined using frequentist fixed (FFE) and random effects (FRE), and Bayesian fixed (BFE) and random effects (BRE) meta-analysis. The pooled parameter estimates were entered into a probabilistic cost-effectiveness Markov model. The four methods of meta-analysis resulted in different parameter estimates and HE outcomes, which were compared with the true values in the reference population. Performance statistics were: (1) the percentage of repetitions that the confidence interval of the probabilistic sensitivity analysis covers the true value (coverage), (2) the difference between the estimated and true value (bias), (3) the mean absolute value of the bias (MAD) and (4) the percentage of repetitions that result in a statistically significant difference between the two interventions (statistical power). As the differences between methods could be due to chance, we repeated every step of the analysis 1,000 times to study whether differences were systematic. Results FFE, FRE and BFE lead to different parameter estimates, but, when entered into the model, they do not lead to large differences in the point estimates of the HE outcomes, even in scenarios where we built in heterogeneity. Random effects methods do not necessarily reduce bias when heterogeneity is added to the trials, and may even increase bias in certain situations. BRE tends to overestimate uncertainty reflected in the CE acceptability curve. Conclusion FFE, FRE and BFE lead to comparable HE outcomes. BRE tends to overestimate uncertainty. Based on this study, we recommend FRE as the preferred method of meta-analysis.
- 5 June 2013
- Published by Springer Nature in PharmacoEconomics
- Vol. 31 (8) , 719-730
A Choice That Matters?
Background Decision-analytic cost-effectiveness (CE) models combine many different parameters like transition probabilities, event probabilities, utilities and costs, which are often obtained after meta-analysis. The method of meta-analysis may affect the CE estimate. Aim Our aim was to perform a simulation study that compares the performance of different methods of meta-analysis, especially with respect to model-based health economic (HE) outcomes. Methods A reference patient population of 50,000 was simulated from which sets of samples were drawn. Each sample drawn represented a clinical trial comparing two fictitious interventions. In several scenarios, the heterogeneity between these trials was varied, by drawing one or more of the trials from predefined subpopulations. Parameter estimates from these trials were combined using frequentist fixed (FFE) and random effects (FRE), and Bayesian fixed (BFE) and random effects (BRE) meta-analysis. The pooled parameter estimates were entered into a probabilistic cost-effectiveness Markov model. The four methods of meta-analysis resulted in different parameter estimates and HE outcomes, which were compared with the true values in the reference population. Performance statistics were: (1) the percentage of repetitions that the confidence interval of the probabilistic sensitivity analysis covers the true value (coverage), (2) the difference between the estimated and true value (bias), (3) the mean absolute value of the bias (MAD) and (4) the percentage of repetitions that result in a statistically significant difference between the two interventions (statistical power). As the differences between methods could be due to chance, we repeated every step of the analysis 1,000 times to study whether differences were systematic. Results FFE, FRE and BFE lead to different parameter estimates, but, when entered into the model, they do not lead to large differences in the point estimates of the HE outcomes, even in scenarios where we built in heterogeneity. Random effects methods do not necessarily reduce bias when heterogeneity is added to the trials, and may even increase bias in certain situations. BRE tends to overestimate uncertainty reflected in the CE acceptability curve. Conclusion FFE, FRE and BFE lead to comparable HE outcomes. BRE tends to overestimate uncertainty. Based on this study, we recommend FRE as the preferred method of meta-analysis.
- 1 November 2012
- Published by Elsevier in Value in Health
- Vol. 15 (7) , A475
PRM83 Comparing Methods of Mixed Treatment Comparisons in Health Economic Models
- 1 November 2012
- Published by Elsevier in Value in Health
- Vol. 15 (7) , A475
PRM83 Comparing Methods of Mixed Treatment Comparisons in Health Economic Models
- 1 November 2011
- Published by Elsevier in Value in Health
- Vol. 14 (7) , A235
DA2 A Choice that Matters: Comparing Methods of Data Synthesis in Cost-Effectiveness Modelling
- 1 November 2011
- Published by Elsevier in Value in Health
- Vol. 14 (7) , A235
DA2 A Choice that Matters: Comparing Methods of Data Synthesis in Cost-Effectiveness Modelling
- 1 November 2010
- Published by Elsevier in Value in Health
- Vol. 13 (7) , A323
PRS27 COUNTRY ADAPTATION OF A HEALTH ECONOMIC MODEL:THE CASE FOR ROFLUMILAST IN THE NETHERLANDS
- 1 November 2010
- Published by Elsevier in Value in Health
- Vol. 13 (7) , A323
PRS27 COUNTRY ADAPTATION OF A HEALTH ECONOMIC MODEL:THE CASE FOR ROFLUMILAST IN THE NETHERLANDS